Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection.

ABSTRACT:

Background

This study aimed to consider the main risk factors related to adverse clinical outcomes in MS patients with COVID-19.

Methods

Using the electronic health records systems, this is a cross-sectional study of two years of hospital admissions in terms of COVID-19 in Iran from March 2019 to August 2021. The severities of COVID-19 outcomes were admitted to ICU, hospitalization days, and in-hospital mortality.

Results

A total of 1634 hospitalized MS patients with a definite diagnosis of COVID-19 based on PCR were recorded in the electronic health systems. MS patients had a 7% increased risk for longer hospitalization, a 3% increased risk for the need to the ICU, and no increased risk of mortality compared with the general population. MS patients who were taking im

SUBMITTER: Maghbooli Z 

PROVIDER: S-EPMC9306262 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature